Matthew A Miller1,2, Yee Ming Lee2. 1. Department of Pharmacy Services, University of Colorado Hospital, Aurora, CO, USA. 2. Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, 12850 E Montview Blvd, Mail Stop C238, Aurora, CO 80045, USA.
Abstract
PURPOSE OF REVIEW: This review summarizes recent literature for applying pharmacogenomics to antifungal selection and dosing, providing an approach to implementing antifungal pharmacogenomics in clinical practice. RECENT FINDINGS: The Clinical Pharmacogenetics Implementation Consortium published guidelines on CYP2C19 and voriconazole, with recommendations to use alternative antifungals or adjust voriconazole dose with close therapeutic drug monitoring (TDM). Recent studies demonstrate an association between CYP2C19 phenotype and voriconazole levels, clinical outcomes, and adverse events. Additionally, CYP2C19-guided preemptive dose adjustment demonstrated benefit in two prospective studies for prophylaxis. Pharmacokinetic-pharmacodynamic modeling studies have generated proposed voriconazole treatment doses based on CYP2C19 phenotypes, with further validation studies needed. SUMMARY: Sufficient evidence is available for implementing CYP2C19-guided voriconazole selection and dosing among select patients at risk for invasive fungal infections. The institution needs appropriate infrastructure for pharmacogenomic testing, integration of results in the clinical decision process, with TDM confirmation of goal trough achievement, to integrate antifungal pharmacogenomics into routine clinical care.
PURPOSE OF REVIEW: This review summarizes recent literature for applying pharmacogenomics to antifungal selection and dosing, providing an approach to implementing antifungal pharmacogenomics in clinical practice. RECENT FINDINGS: The Clinical Pharmacogenetics Implementation Consortium published guidelines on CYP2C19 and voriconazole, with recommendations to use alternative antifungals or adjust voriconazole dose with close therapeutic drug monitoring (TDM). Recent studies demonstrate an association between CYP2C19 phenotype and voriconazole levels, clinical outcomes, and adverse events. Additionally, CYP2C19-guided preemptive dose adjustment demonstrated benefit in two prospective studies for prophylaxis. Pharmacokinetic-pharmacodynamic modeling studies have generated proposed voriconazole treatment doses based on CYP2C19 phenotypes, with further validation studies needed. SUMMARY: Sufficient evidence is available for implementing CYP2C19-guided voriconazole selection and dosing among select patients at risk for invasive fungal infections. The institution needs appropriate infrastructure for pharmacogenomic testing, integration of results in the clinical decision process, with TDM confirmation of goal trough achievement, to integrate antifungal pharmacogenomics into routine clinical care.
Authors: Joachim D Weigel; Nicole G M Hunfeld; Birgit C P Koch; Mohamud Egal; Jan Bakker; Ron H N van Schaik; Teun van Gelder Journal: Intensive Care Med Date: 2015-08-04 Impact factor: 17.440
Authors: J Kevin Hicks; Blanca E Gonzalez; Anthony S Zembillas; Karissa Kusick; Sudish Murthy; Siva Raja; Steven M Gordon; Rabi Hanna Journal: Pharmacogenomics Date: 2016-05-04 Impact factor: 2.533
Authors: B Moriyama; A Owusu Obeng; J Barbarino; S R Penzak; S A Henning; S A Scott; Jag Agúndez; J R Wingard; H L McLeod; T E Klein; S J Cross; K E Caudle; T J Walsh Journal: Clin Pharmacol Ther Date: 2017-04-18 Impact factor: 6.875
Authors: Aniwaa Owusu Obeng; Eric F Egelund; Abdullah Alsultan; Charles A Peloquin; Julie A Johnson Journal: Pharmacotherapy Date: 2014-02-07 Impact factor: 4.705
Authors: J A Luzum; R E Pakyz; A R Elsey; C E Haidar; J F Peterson; M Whirl-Carrillo; S K Handelman; K Palmer; J M Pulley; M Beller; J S Schildcrout; J R Field; K W Weitzel; R M Cooper-DeHoff; L H Cavallari; P H O'Donnell; R B Altman; N Pereira; M J Ratain; D M Roden; P J Embi; W Sadee; T E Klein; J A Johnson; M V Relling; L Wang; R M Weinshilboum; A R Shuldiner; R R Freimuth Journal: Clin Pharmacol Ther Date: 2017-06-09 Impact factor: 6.875
Authors: Nina R Sperber; Janet S Carpenter; Larisa H Cavallari; Laura J Damschroder; Rhonda M Cooper-DeHoff; Joshua C Denny; Geoffrey S Ginsburg; Yue Guan; Carol R Horowitz; Kenneth D Levy; Mia A Levy; Ebony B Madden; Michael E Matheny; Toni I Pollin; Victoria M Pratt; Marc Rosenman; Corrine I Voils; Kristen W Weitzel; Russell A Wilke; R Ryanne Wu; Lori A Orlando Journal: BMC Med Genomics Date: 2017-05-22 Impact factor: 3.063